DOCSLIB.ORG

Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer SUPPLEMENTARY: Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer Tao Zuo, Ta-Ming Liu, Xun Lan, Yu-I Weng, Rulong Shen, Fei Gu, Yi-Wen Huang, Sandya Liyanarachchi, Daniel E. Deatherage, Pei-Yin Hsu, Cenny Taslim, Bhuvaneswari Ramaswamy, Charles L. Shapiro, Huey-Jen L. Lin, Alfred S. L. Cheng, Victor X. Jin, and Tim H.-M. Huang 1 Table of Content: 1. Fig. S1. Elevated AKT1 kinase activity in myrAKT1- transfected MCF10A cells. ---------------------------------------------------------------------------------------------------- page 4 2. Fig. S2. Genome-wide view of H3K27me3 in mammary epithelial cells. ---------------------------------------------------------------------------------------------------- page 5 3. Fig. S3. Biological functions of PI3K/AKT- downstream genes. ----------------- page 6 4. Fig. S4. Genomic maps of 40 genes. ------------------------------------------------- page 8 5. Fig. S5. Comparing DNA methylation levels of four CpG islands measured by meDIP-qPCR and MassARRAY.------------------------------------------------------- page 11 6. Fig. S6. Validation of DNA methylation by MBDCap-seq.----------------------- page 13 7. Table S1. Summary of H3K27me3 ChIP-seq data ------------------------------ page 14 8. Table S2. Distribution of H3K27me3 in MCF10A genome ---------------------- page 14 9. Table S3. Genes (n=488) enriched with H3K27me3 and downregulated by PI3K/AKT- signaling ---------------------------------------------------------------------- page 15 10. Table S4. Genes (n=1005) enriched with H3K27me3 but without downregulation -------------------------------------------------------------------------------------------------- page 26 11. Table S5. Genes (n=723) downregulated by PI3K/AKT- but without enrichment of H3K27me3 ---------------------------------------------------------------------------------- page 45 2 12. Table S6. Summary of 21 breast cancer cell lines -------------------------------- page 60 13. Table S7. Summary of in silico expression values of 180 genes in 21 breast cancer lines and 4 normal human mammary epithelial samples (HMECs) -------------------------------------------------------------------------------------------------- page 62 14. Table S8. ChIP-qPCR of H3K27me3 in 21 breast cancer cell lines and 4 HMECs -------------------------------------------------------------------------------------------------- page 66 15. Table S9. meDIP-qPCR in 21 breast cancer lines, 4 HMECs and myrAKT1- or Vector transfected MCF10A cells ----------------------------------------------------- page 68 16. Table S10. PCR primers of 40 genes ------------------------------------------------ page 70 17. Table S11. Gene expression after drug treatment -------------------------------- page 71 18. Table S12. RT-PCR primers of 40 genes ------------------------------------------- page 75 19. Table S13. MassARRAY PCR primers of 4 genes -------------------------------- page 76 20. Table S14. Summary of MBDCap-seq data ---------------------------------------- page 76 21. Table S15. Differentially methylated genes (n=143) identified by MBDCap-seq analysis .-------------------------------------------------------------------------------------- page 76 22. Experimental procedures ---------------------------------------------------------------- page 79 23. Reference ----------------------------------------------------------------------------------- page 80 3 SUPPLEMENTAL DATA: Fig. S1. Elevated AKT1 kinase activity in myrAKT1- transfected MCF10A cells. AKT1 kinase activity increased 4-fold in myrAKT1- transfected MCF10A compared with vector control cells. 4 Fig. S2. Genome-wide view of H3K27me3 in mammary epithelial cells. Top 1% enrichment regions of H3K27me3 are indicated as bars in the figure, i.e., AKT1 (Red) and Vector (Green) transfected MCF10A. Disseminated bars were matched to corresponding locations at chromosome bands in each of 23 chromosomes in the human genome. H3K27me3 enrichment was identified by the ChIP-seq peak calling program, bin-base enrichment thresholds (BELT) algorithm (Frietze et al., 2010; Cited in main text), with a False Discovery Rate (FDR) less than 0.05. 5 Fig. S3. Biological functions of PI3K/AKT- downstream genes. Functional analyses were performed using IPA (Ingenuity Pathway Analysis) software. PI3K/AKT- downstream targets were divided into three sets according to their gene expression and H3K27me3 status shown in Figure1D. Then gene lists were uploaded to IPA for statistical analyses. Of 488 genes marked by H3K27me3 and downregulated by AKT1, 172 genes (Table S3) are related to cancer (p = 9.74 x 10−13), while p values are 8.55 x 10−3 (19 of 1005 genes, Table S4) and 2.05 x 10−9 (207 of 723 genes, Table S5) in other two groups respectively. As shown in figure, the y-axis indicates negative exponent of the p-value, the results of three categories are ordered parallel within each 6 function. 12 biological functions shown in figure are most significant ones derived from the analysis of 488 genes. 7 Figure S4 8 Figure S4 9 Figure S4 Fig. S4. Genomic maps of 40 genes. A total of 40 genes, as shown in Figure 3A, were subjected to meDIP- and ChIP-qPCR assays. As shown in the figure, genomic maps illustrate distribution of CpG sites (vertical bars) and locations of PCR primers (head-to-head arrows) around TSS region at each locus. 10 Figure S5 11 Fig. S5. Comparing DNA methylation levels of four CpG islands measured by meDIP-qPCR and MassARRAY . A, genomic maps show CpG islands at promoter regions of four genes, i.e., SFRP1, HOXA5, HOXA9, and SYNE2. Transcription start sites (TSSs) and locations of PCR primers were indicated in maps. B, DNA methylation levels of these 4 genes in 20 breast cancer cell lines and 4 normal breast epithelial cell samples (Fig.3 and 4) were assessed by meDIP-qPCR and MassARRAY, respectively. Pearson's correlation analysis was conducted to compare methylation levels measured by these two methods. The linear regression r-squared (r2) values were shown in figure. Methylation levels measured at the SYNE2 CpG island show the strongest correlation. 12 Figure S6 Fig. S6. Validation of DNA methylation by MBDCap-seq. Box plot represents DNA methylation of 180 loci identified in Fig. 2A. Two of loci were not found in the MBDCap-seq dataset. Methylation levels were assessed by MBDCap- seq in T-47D cells treated with DAC and/or LY294002. Significance of differences among drug treatments was determined by Student’s t-test. *P<0.05, **P<0.01. 13 a Table S1. Summary of H3K27me3 ChIP-seq data AKT1 Vector Subtracted Reads 40,585,026 27,308,019 - Mapped Reads 21,195,941 17,394,048 - Unique Mapped Reads 15,589,956 11,789,771 - Peaks (Top 1%) 12,113 9,743 11,577 Peaks (Top 2%) 27,688 19,229 20,656 Peaks (Top 10%) 130,709 130,075 122,727 Note: a) ChIP-Seq analysis is described in Experimental procedures. a Table S2. Distribution of H3K27me3 in MCF10A genome AKT1 Vector Subtracted Gene desert (>100-kb) 43,104 44,129 42,081 5' distal (-100 to -4-kb) 20,553 19,821 18,030 5' TSS (-4 to 2-kb) 7,485 7,232 6,154 Intragenic 39,454 39,237 39,050 3' end (<10-kb) 4,168 3,936 3,682 3' distal (>10-kb) 15,945 15,720 13,730 Total 130,709 130,075 122,727 Note: a) Genome-wide distribution of top 10% H3K27me3 peaks were shown in table. 14 Table S3. Genes (n=488) enriched with H3K27me3 and downregulated by PI3K/AKT signaling Expressio H3K27me3 Polycomb Gene b Affymetrix c d Cancer a Accession Chr. n folds peak targets in f Symbol (Strand) Prob_ID (AKT1 vs. (distance to e related ES cells Vector) TSS [bp]) A2ML1 NM_144670 12(+) 1564307_a_at -9.83 1950 ABCA12 NM_173076 2(-) 215465_at -25.70 1838 ABCA5 NM_018672 17(-) 213353_at -3.59 1223 Yes Yes ABCA8 NM_007168 17(-) 204719_at -6.52 1265 Yes Yes ABCC2 NM_000392 10(+) 206155_at -4.06 -1454 Yes ABHD4 NM_022060 14(+) 218581_at -1.90 1637 NM_001003 ABLIM1 10(-) 200965_s_at -1.78 1172 408 ACACB NM_001093 12(+) 49452_at -4.09 -715 ACPL2 NM_152282 3(+) 226925_at -4.11 -1331 Yes ADD3 NM_016824 10(+) 201753_s_at -3.66 -1176 Yes ADRB2 NM_000024 5(+) 206170_at -1.76 1660 Yes Yes AFTPH NM_203437 2(+) 222472_at -1.58 -395 AGA NM_000027 4(-) 204333_s_at -1.63 918 AGPAT4 NM_020133 6(-) 228667_at -2.70 1924 AKR1C3 NM_003739 10(+) 209160_at -1.75 1127 Yes NM_001031 ALDH3A2 17(+) 202054_s_at -1.74 507 806 ALOX5AP NM_001629 13(+) 204174_at -2.41 -1493 AMOTL1 NM_130847 11(+) 225450_at -1.71 1221 AMY2B NM_020978 1(+) 228023_x_at -1.71 -590 Yes ► ANKRA2 NM_023039 5(-) 218769_s_at -1.85 -716 ANKRD38 NM_181712 1(-) 229125_at -3.83 -1945 Yes ANXA3 NM_005139 4(+) 209369_at -2.23 -63 AP1M2 NM_005498 19(-) 65517_at -4.80 957 ARHGAP29 NM_004815 1(-) 1558280_s_at -4.70 867 Yes ARHGAP8 NM_181335 22(+) 37117_at -7.57 -362 Yes ARL6IP NM_015161 16(-) 211935_at -2.21 1448 Yes ARRDC3 NM_020801 5(-) 224797_at -2.72 1410 ASAH1 NM_004315 8(-) 213702_x_at -1.55 -1898 Yes ASPM NM_018136 1(-) 219918_s_at -2.57 -247 ASS1 NM_000050 9(+) 207076_s_at -3.78 -905 Yes ATP9A NM_006045 20(-) 212062_at -11.16 -1497 ATXN1 NM_000332 6(-) 203232_s_at -5.25 533 ► AUH NM_001698 9(-) 205052_at -1.76 1882 AYTL1 NM_017839 16(+) 227889_at -1.81 -1716 B3GALTL NM_194318 13(+) 227083_at -1.50 -568 BAMBI NM_012342 10(+) 203304_at -2.86 -1594 Yes Yes BBX NM_020235 3(+) 223135_s_at -1.60 -1856 BDH2 NM_020139 4(-) 218285_s_at -1.74 1924 NM_001007 BRWD1 21(-) 231960_at -1.62 413 246 BSDC1 NM_018045 1(-) 218004_at -1.75 -247 BTG1 NM_001731 12(-) 200920_s_at -1.73 -134 ► BTG2 NM_006763 1(+) 201236_s_at -1.61 1429 Yes Yes 15 BTN3A3 NM_006994 6(+) 204821_at -3.08 1504 C10orf58 NM_032333 10(+)
Load more

Recommended publications
  • Genetic Variation Across the Human Olfactory Receptor Repertoire Alters Odor Perception
    bioRxiv preprint doi: https://doi.org/10.1101/212431; this version posted November 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Genetic variation across the human olfactory receptor repertoire alters odor perception Casey Trimmer1,*, Andreas Keller2, Nicolle R. Murphy1, Lindsey L. Snyder1, Jason R. Willer3, Maira Nagai4,5, Nicholas Katsanis3, Leslie B. Vosshall2,6,7, Hiroaki Matsunami4,8, and Joel D. Mainland1,9 1Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA 2Laboratory of Neurogenetics and Behavior, The Rockefeller University, New York, New York, USA 3Center for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, USA 4Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA 5Department of Biochemistry, University of Sao Paulo, Sao Paulo, Brazil 6Howard Hughes Medical Institute, New York, New York, USA 7Kavli Neural Systems Institute, New York, New York, USA 8Department of Neurobiology and Duke Institute for Brain Sciences, Duke University Medical Center, Durham, North Carolina, USA 9Department of Neuroscience, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA *[email protected] ABSTRACT The human olfactory receptor repertoire is characterized by an abundance of genetic variation that affects receptor response, but the perceptual effects of this variation are unclear. To address this issue, we sequenced the OR repertoire in 332 individuals and examined the relationship between genetic variation and 276 olfactory phenotypes, including the perceived intensity and pleasantness of 68 odorants at two concentrations, detection thresholds of three odorants, and general olfactory acuity.
    [Show full text]
  • The Title of the Article
    Mechanism-Anchored Profiling Derived from Epigenetic Networks Predicts Outcome in Acute Lymphoblastic Leukemia Xinan Yang, PhD1, Yong Huang, MD1, James L Chen, MD1, Jianming Xie, MSc2, Xiao Sun, PhD2, Yves A Lussier, MD1,3,4§ 1Center for Biomedical Informatics and Section of Genetic Medicine, Department of Medicine, The University of Chicago, Chicago, IL 60637 USA 2State Key Laboratory of Bioelectronics, Southeast University, 210096 Nanjing, P.R.China 3The University of Chicago Cancer Research Center, and The Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL 60637 USA 4The Institute for Genomics and Systems Biology, and the Computational Institute, The University of Chicago, Chicago, IL 60637 USA §Corresponding author Email addresses: XY: [email protected] YH: [email protected] JC: [email protected] JX: [email protected] XS: [email protected] YL: [email protected] - 1 - Abstract Background Current outcome predictors based on “molecular profiling” rely on gene lists selected without consideration for their molecular mechanisms. This study was designed to demonstrate that we could learn about genes related to a specific mechanism and further use this knowledge to predict outcome in patients – a paradigm shift towards accurate “mechanism-anchored profiling”. We propose a novel algorithm, PGnet, which predicts a tripartite mechanism-anchored network associated to epigenetic regulation consisting of phenotypes, genes and mechanisms. Genes termed as GEMs in this network meet all of the following criteria: (i) they are co-expressed with genes known to be involved in the biological mechanism of interest, (ii) they are also differentially expressed between distinct phenotypes relevant to the study, and (iii) as a biomodule, genes correlate with both the mechanism and the phenotype.
    [Show full text]
  • Sample Lab Report
    3030 Venture Lane, Suite 108 ● Melbourne, Florida 32934 ● Phone 321-253-5197 ● Fax 321-253-5199 PATIENT: DOE, JAMES ACCESSION NO: CLINICIAN/ PATIENT ID: REQUESTING DATE OF BIRTH: 1/5/1986 DOCTOR: GENDER: MALE DATE COLLECTED: 5/26/2015 DATE OF REPORT: 6/15/2015 RESULTS PRIMARY TUMOR TYPE RIGHT TESTICLE BIOLOGICALLY IMPORTANT ONCOGENES DETECTED GENE IMPLICATION TP53 TP53 mutations may be an important driver of tumorigenesis and / or a reason for treatment resistance in a some patients. PTEN Responsible for uncontrolled growth. MDM2 Causes p53 inactivation. Associated with cancer growth and progression. TGFB1 TGFB appears to promote tumor progession by stimulating invasion and metastasis. TUBB2A Microtubules are the key components of the cytoskeleton of eukaryotic cells and have an important role in various cellular functions such as intracellular migration and transport, cell shape maintenance, polarity, cell signaling and mitosis. c-JUN Proto-oncogene PHB2 Prohibitins play a crucial role in adhesion processes in the cell and thereby sustaining cancer cell propagation and survival. Clinical Impression: Low Aggressive Potential Additional Genes Detected: ABCG2, ARHGAP5, ATF4, BIRC5, BNIP3, CAPNS1, CARD17, CCNB1, CD24, CDC20, CDK18, CKS2, DCN, DEPDC1, FTL, FZD5, FZD9, GAPDH, GNB2, GPR126, H2AFZ, HDAC1, HMGN2, ID1, IFITM1, JUNB, KPNA2, KRT18, LDHA, LTF, MAD2L1, MAP2K1, MAP2K2, MAP2K4, MAPRE1, MAS1, NME1, NME3, NPM1, PA2G4, PABPC1, PFDN4, PGAM1, PGK1, PHB, PIK3CB, PKM, PPIA, PPIH, PRKX, PRNP, PTMA, RAC1, RAC2, RALBP1, RAP1A, RBBP4, RHOB, RHOC,
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin
    cells Review Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin Agnieszka Bochy ´nska,Juliane Lüscher-Firzlaff and Bernhard Lüscher * ID Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Pauwelsstrasse 30, 52057 Aachen, Germany; [email protected] (A.B.); jluescher-fi[email protected] (J.L.-F.) * Correspondence: [email protected]; Tel.: +49-241-8088850; Fax: +49-241-8082427 Received: 18 January 2018; Accepted: 27 February 2018; Published: 2 March 2018 Abstract: Regulation of gene expression is achieved by sequence-specific transcriptional regulators, which convey the information that is contained in the sequence of DNA into RNA polymerase activity. This is achieved by the recruitment of transcriptional co-factors. One of the consequences of co-factor recruitment is the control of specific properties of nucleosomes, the basic units of chromatin, and their protein components, the core histones. The main principles are to regulate the position and the characteristics of nucleosomes. The latter includes modulating the composition of core histones and their variants that are integrated into nucleosomes, and the post-translational modification of these histones referred to as histone marks. One of these marks is the methylation of lysine 4 of the core histone H3 (H3K4). While mono-methylation of H3K4 (H3K4me1) is located preferentially at active enhancers, tri-methylation (H3K4me3) is a mark found at open and potentially active promoters. Thus, H3K4 methylation is typically associated with gene transcription. The class 2 lysine methyltransferases (KMTs) are the main enzymes that methylate H3K4. KMT2 enzymes function in complexes that contain a necessary core complex composed of WDR5, RBBP5, ASH2L, and DPY30, the so-called WRAD complex.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Human Artificial Chromosome (Hac) Vector
    Europäisches Patentamt *EP001559782A1* (19) European Patent Office Office européen des brevets (11) EP 1 559 782 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: C12N 15/09, C12N 1/15, 03.08.2005 Bulletin 2005/31 C12N 1/19, C12N 1/21, C12N 5/10, C12P 21/02 (21) Application number: 03751334.8 (86) International application number: (22) Date of filing: 03.10.2003 PCT/JP2003/012734 (87) International publication number: WO 2004/031385 (15.04.2004 Gazette 2004/16) (84) Designated Contracting States: • KATOH, Motonobu, Tottori University AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Yonago-shi, Tottori 683-8503 (JP) HU IE IT LI LU MC NL PT RO SE SI SK TR • TOMIZUKA, Kazuma, Designated Extension States: Kirin Beer Kabushiki Kaisha AL LT LV MK Takashi-shi, Gunma 370-1295 (JP) • KUROIWA, Yoshimi, (30) Priority: 04.10.2002 JP 2002292853 Kirin Beer Kabushiki Kaisha Takasaki-shi, Gunma 370-1295 (JP) (71) Applicant: KIRIN BEER KABUSHIKI KAISHA • KAKEDA, Minoru, Kirin Beer Kabushiki Kaisha Tokyo 104-8288 (JP) Takasaki-shi, Gunma 370-1295 (JP) (72) Inventors: (74) Representative: HOFFMANN - EITLE • OSHIMURA, Mitsuo, Tottori University Patent- und Rechtsanwälte Yonago-shi, Tottori 683-8503 (JP) Arabellastrasse 4 81925 München (DE) (54) HUMAN ARTIFICIAL CHROMOSOME (HAC) VECTOR (57) The present invention relates to a human arti- ing a cell which expresses foreign DNA. Furthermore, ficial chromosome (HAC) vector and a method for pro- the present invention relates to a method for producing ducing the same.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Copy Number Variation in Fetal Alcohol Spectrum Disorder
    Biochemistry and Cell Biology Copy number variation in fetal alcohol spectrum disorder Journal: Biochemistry and Cell Biology Manuscript ID bcb-2017-0241.R1 Manuscript Type: Article Date Submitted by the Author: 09-Nov-2017 Complete List of Authors: Zarrei, Mehdi; The Centre for Applied Genomics Hicks, Geoffrey G.; University of Manitoba College of Medicine, Regenerative Medicine Reynolds, James N.; Queen's University School of Medicine, Biomedical and Molecular SciencesDraft Thiruvahindrapuram, Bhooma; The Centre for Applied Genomics Engchuan, Worrawat; Hospital for Sick Children SickKids Learning Institute Pind, Molly; University of Manitoba College of Medicine, Regenerative Medicine Lamoureux, Sylvia; The Centre for Applied Genomics Wei, John; The Centre for Applied Genomics Wang, Zhouzhi; The Centre for Applied Genomics Marshall, Christian R.; The Centre for Applied Genomics Wintle, Richard; The Centre for Applied Genomics Chudley, Albert; University of Manitoba Scherer, Stephen W.; The Centre for Applied Genomics Is the invited manuscript for consideration in a Special Fetal Alcohol Spectrum Disorder Issue? : Keyword: Fetal alcohol spectrum disorder, FASD, copy number variations, CNV https://mc06.manuscriptcentral.com/bcb-pubs Page 1 of 354 Biochemistry and Cell Biology 1 Copy number variation in fetal alcohol spectrum disorder 2 Mehdi Zarrei,a Geoffrey G. Hicks,b James N. Reynolds,c,d Bhooma Thiruvahindrapuram,a 3 Worrawat Engchuan,a Molly Pind,b Sylvia Lamoureux,a John Wei,a Zhouzhi Wang,a Christian R. 4 Marshall,a Richard F. Wintle,a Albert E. Chudleye,f and Stephen W. Scherer,a,g 5 aThe Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital 6 for Sick Children, Toronto, Ontario, Canada 7 bRegenerative Medicine Program, University of Manitoba, Winnipeg, Canada 8 cCentre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Loss of 18Q22.3 Involving the Carboxypeptidase of Glutamate-Like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer
    Published OnlineFirst November 29, 2011; DOI: 10.1158/1078-0432.CCR-11-1903 Clinical Cancer Imaging, Diagnosis, Prognosis Research Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer Jih-Hsiang Lee1, Elisa Giovannetti4, Jin-Hyeok Hwang1,5, Iacopo Petrini1, Qiuyan Wang1, Johannes Voortman1,4, Yonghong Wang2, Seth M. Steinberg3, Niccola Funel6, Paul S. Meltzer2, Yisong Wang1, and Giuseppe Giaccone1 Abstract Purposes: Pancreatic cancer is the fourth leading cause of cancer-related death, and studies on the clinical relevance of its genomic imbalances are warranted. Experimental Design: Recurrent copy number alterations of cytobands and genes were analyzed by array comparative genomic hybridization (aCGH) in 44 resected pancreatic cancer specimens. Prognostic markers identified by aCGH were validated by PCR gene copy number assay in an independent validation cohort of 61 resected pancreatic cancers. The functions of gene identified were evaluated by proliferation, cell cycle, and migration assays in pancreatic cancer cells. Results: We showed recurrent copy number gains and losses in the first cohort. Loss of 18q22.3 was significantly associated with short-term overall survival in the first cohort (P ¼ 0.019). This cytoband includes the carboxypeptidase of glutamate-like (CPGL) gene. CPGL gene deletion was associated with shorter overall survival in the validation cohort (P ¼ 0.003). CPGL deletion and mutations of TP53 or Kras seem to be independent events. A Cox model analysis of the two cohorts combined showed that loss of 18q22.3/deletion of the CPGL gene was an independent poor prognostic factor for overall survival (HR ¼ 2.72, P ¼ 0.0007).
    [Show full text]
  • OR1J1 Rabbit Pab Antibody
    OR1J1 rabbit pAb antibody Catalog No : Source: Concentration : Mol.Wt. (Da): A19043 Rabbit 1 mg/ml Applications WB,ELISA Reactivity Human Dilution WB 1:500-2000 ELISA 1:5000-20000 Storage -20°C/1 year Specificity OR1J1 Polyclonal Antibody detects endogenous levels of protein. Source / Purification The antibody was affinity-purified from rabbit antiserum by affinity- chromatography using epitope-specific immunogen. Immunogen Synthesized peptide derived from part region of human protein Uniprot No Q8NGS3 Alternative names Form Liquid in PBS containing 50% glycerol, and 0.02% sodium azide. Clonality Polyclonal Isotype IgG Conjugation Background olfactory receptor family 1 subfamily J member 1(OR1J1) Homo sapiens Olfactory receptors interact with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell. The olfactory receptor proteins are members of a large family of G-protein-coupled receptors (GPCR) arising from single coding-exon genes. Olfactory receptors share a 7-transmembrane domain structure with many neurotransmitter and hormone receptors and are responsible for the recognition and G protein- mediated transduction of odorant signals. The olfactory receptor gene family is the largest in the genome. The nomenclature assigned to the olfactory receptor genes and proteins for this organism is independent of other organisms. [provided by RefSeq, Jul 2008], Other OR1J1, Olfactory receptor 1J1 (Olfactory receptor OR9-18) Produtc Images： A AAB Biosciences Products www.aabsci.cn FOR RESEARCH USE ONLY. NOT FOR HUMAN OR DIAGNOSTIC USE. Application Key: WB-Western IP-Immunoprecipitation IHC-Immunohistochemistry ChIP-Chromatin Immunoprecipitation IF-Immunofluorescence F-Flow Cytometry E-P-ELISA-Peptide Species Cross-Reactivity Key: H-Human M-Mouse R-Rat Hm-Hamster Mk-Monkey Vir-Virus Mi-Mink C-Chicken Dm-D.
    [Show full text]